Nelson memo

The Nelson Memo: Igniting a Global Open Data Revolution

The landscape of scientific research is undergoing a seismic shift, driven by an urgent demand for transparency, reproducibility, and equitable access. At the epicenter of this transformation in the United States is the Nelson Memo, a policy directive rapidly accelerating the future of open science. With the National Institutes of Health (NIH)'s recent announcement (NOT-OD-25-101)…...
Read More

Top Stories

MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook

At the MAPS Americas 2025 conference in New Orleans, one of...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
AI, ML, NLP, AR/VR, Blockchain in Healthcare

Emerging Technologies: Healthcare Communication Friend or Foe?

Embracing emerging technologies and innovations is not just an option but a necessity for biopharma...
Periodic Safety Update Report (PSUR) - Medical Device

Periodic Safety Update Report (PSUR): A Breakdown of MDCG 2022-21

A well-structured, clear, and concise PSUR enables a seamless notified body review. Read our key...

Launch Excellence: The Path Forward for Medical Affairs

Learn how Medical Affairs can redefine launch excellence by streamlining the journey from clinical trial...
Medical Device Regulation

Clinical Evidence: How Much Is Enough?

Ensuring the safety and functionality of your medical device is vital. But how much clinical...
Data-driven QMS Alignment-Feature image for the 30-sec video reel - AMDS

Medical Device Manufacturing: Risk-Based QMS Alignment for EU MDR

The latest EU-MDR guidelines are a step in the right direction, moving from a focus...
Plain Language Clinical Trial Summaries

Why Do Plain Language Clinical Trial Summaries Matter?

Did you know that the European Medicines Agency’s Clinical Trials Regulation comes into effect on...

Learn more ABOUT our company.